Shin-ichiro Takayanagi
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML.
Journal: Leukemia
Published: January 30, 2025
Acquired angioedema as a late-onset complication after cord blood transplantation: a subtype of chronic graft-versus-host disease.
Journal: QJM : monthly journal of the Association of Physicians
Published: April 07, 2024
Mini-TCRs: Truncated T cell receptors to generate T cells from induced pluripotent stem cells.
Journal: Molecular therapy. Methods & clinical development
Published: July 08, 2022
TFEB-mediated endolysosomal activity controls human hematopoietic stem cell fate.
Journal: Cell stem cell
Published: April 22, 2021
Sphingosine-1-phosphate receptor 3 potentiates inflammatory programs in normal and leukemia stem cells to promote differentiation.
Journal: Blood cancer discovery
Published: January 18, 2021
A latent subset of human hematopoietic stem cells resists regenerative stress to preserve stemness.
Journal: Nature immunology
Published: October 05, 2020
Engineering of human induced pluripotent stem cells via human artificial chromosome vectors for cell therapy and disease modeling.
Journal: Molecular therapy. Nucleic acids
Published: June 29, 2020
The Transition from Quiescent to Activated States in Human Hematopoietic Stem Cells Is Governed by Dynamic 3D Genome Reorganization.
Journal: Cell stem cell
Published: May 22, 2020
A stemness screen reveals C3orf54/INKA1 as a promoter of human leukemia stem cell latency.
Journal: Blood
Published: October 19, 2018
57R2A, a newly established monoclonal antibody against mouse GPR56, marks long-term repopulating hematopoietic stem cells.
Journal: Experimental hematology
Published: April 02, 2017
Last Updated: 09/26/2026